Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660.
Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98(19):10869–74. https://doi.org/10.1073/pnas.191367098.
CAS Article PubMed PubMed Central Google Scholar
Diamond JR, Eckhardt SG, Tan AC, Newton TP, Selby HM, Brunkow KL, Kachaeva MI, Varella-Garcia M, Pitts TM, Bray MR, et al. Predictive biomarkers of sensitivity to the aurora and angiogenic kinase inhibitor ENMD-2076 in preclinical breast cancer models. Clin Cancer Res. 2013;19(1):291–303. https://doi.org/10.1158/1078-0432.CCR-12-1611.
CAS Article PubMed Google Scholar
Jalalirad M, Haddad TC, Salisbury JL, Radisky D, Zhang M, Schroeder M, Tuma A, Leof E, Carter JM, Degnim AC, et al. Aurora-A kinase oncogenic signaling mediates TGF-beta-induced triple-negative breast cancer plasticity and chemoresistance. Oncogene. 2021;40(14):2509–23. https://doi.org/10.1038/s41388-021-01711-x.
CAS Article PubMed PubMed Central Google Scholar
Zeichner SB, Terawaki H, Gogineni K. A review of systemic treatment in metastatic triple-negative breast cancer. Breast Cancer. 2016;10:25–36. https://doi.org/10.4137/BCBCR.S32783.
CAS Article PubMed PubMed Central Google Scholar
El Zein D, Hughes M, Kumar S, Peng X, Oyasiji T, Jabbour H, Khoury T. Metaplastic carcinoma of the breast is more aggressive than triple-negative breast cancer: a study from a single institution and review of literature. Clin Breast Cancer. 2017;17(5):382–91. https://doi.org/10.1016/j.clbc.2017.04.009.
Article PubMed PubMed Central Google Scholar
Tray N, Taff J, Singh B, Suh J, Ngo N, Kwa M, Troxel AB, Chae YK, Kurzrock R, Patel SP, et al. Metaplastic breast cancers: genomic profiling, mutational burden and tumor-infiltrating lymphocytes. Breast. 2019;44:29–32. https://doi.org/10.1016/j.breast.2018.12.010.
Tray N, Taff J, Adams S. Therapeutic landscape of metaplastic breast cancer. Cancer Treat Rev. 2019;79:101888. https://doi.org/10.1016/j.ctrv.2019.08.004.
CAS Article PubMed Google Scholar
Sledge GW Jr. Curing metastatic breast cancer. J Oncol Pract. 2016;12(1):6–10. https://doi.org/10.1200/JOP.2015.008953.
Bertolin G, Tramier M. Insights into the non-mitotic functions of aurora kinase a: more than just cell division. Cell Mol Life Sci. 2020;77(6):1031–47. https://doi.org/10.1007/s00018-019-03310-2.
CAS Article PubMed Google Scholar
Tang A, Gao K, Chu L, Zhang R, Yang J, Zheng J. Aurora kinases: novel therapy targets in cancers. Oncotarget. 2017;8(14):23937–54. https://doi.org/10.18632/oncotarget.14893.
Article PubMed PubMed Central Google Scholar
Tavernier N, Sicheri F, Pintard L. Aurora A kinase activation: different means to different ends. J Cell Biol. 2021;220(9):e202106128. https://doi.org/10.1083/jcb.202106128.
CAS Article PubMed PubMed Central Google Scholar
Cirak Y, Furuncuoglu Y, Yapicier O, Aksu A, Cubukcu E. Aurora A overexpression in breast cancer patients induces taxane resistance and results in worse prognosis. J BUON. 2015;20(6):1414–9.
Boos SL, Loevenich LP, Vosberg S, Engleitner T, Ollinger R, Kumbrink J, Rokavec M, Michl M, Greif PA, Jung A, et al. Disease modeling on tumor organoids implicates AURKA as a therapeutic target in liver metastatic colorectal cancer. Cell Mol Gastroenterol Hepatol. 2021;13(2):517–40. https://doi.org/10.1016/j.jcmgh.2021.10.008.
CAS Article PubMed PubMed Central Google Scholar
Pick E, Kluger Y, Giltnane JM, Moeder C, Camp RL, Rimm DL, Kluger HM. High HSP90 expression is associated with decreased survival in breast cancer. Can Res. 2007;67(7):2932–7. https://doi.org/10.1158/0008-5472.CAN-06-4511.
Blagosklonny MV, Toretsky J, Bohen S, Neckers L. Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90. Proc Natl Acad Sci USA. 1996;93(16):8379–83. https://doi.org/10.1073/pnas.93.16.8379.
CAS Article PubMed PubMed Central Google Scholar
Marei HE, Althani A, Afifi N, Hasan A, Caceci T, Pozzoli G, Morrione A, Giordano A, Cenciarelli C. p53 signaling in cancer progression and therapy. Cancer Cell Int. 2021;21(1):703. https://doi.org/10.1186/s12935-021-02396-8.
CAS Article PubMed PubMed Central Google Scholar
Liu Y, Tavana O, Gu W. p53 modifications: exquisite decorations of the powerful guardian. J Mol Cell Biol. 2019;11(7):564–77. https://doi.org/10.1093/jmcb/mjz060.
CAS Article PubMed PubMed Central Google Scholar
Hu J, Cao J, Topatana W, Juengpanich S, Li S, Zhang B, Shen J, Cai L, Cai X, Chen M. Targeting mutant p53 for cancer therapy: direct and indirect strategies. J Hematol Oncol. 2021;14(1):157. https://doi.org/10.1186/s13045-021-01169-0.
CAS Article PubMed PubMed Central Google Scholar
Ice RJ, McLaughlin SL, Livengood RH, Culp MV, Eddy ER, Ivanov AV, Pugacheva EN. NEDD9 depletion destabilizes Aurora A kinase and heightens the efficacy of Aurora A inhibitors: implications for treatment of metastatic solid tumors. Can Res. 2013;73(10):3168–80. https://doi.org/10.1158/0008-5472.CAN-12-4008.
Miralaei N, Majd A, Ghaedi K, Peymani M, Safaei M. Integrated pan-cancer of AURKA expression and drug sensitivity analysis reveals increased expression of AURKA is responsible for drug resistance. Cancer Med. 2021;10(18):6428–41. https://doi.org/10.1002/cam4.4161.
CAS Article PubMed PubMed Central Google Scholar
Yang H, He L, Kruk P, Nicosia SV, Cheng JQ. Aurora-A induces cell survival and chemoresistance by activation of Akt through a p53-dependent manner in ovarian cancer cells. Int J Cancer. 2006;119(10):2304–12. https://doi.org/10.1002/ijc.22154.
CAS Article PubMed Google Scholar
Li Y, Tang K, Zhang H, Zhang Y, Zhou W, Chen X. Function of Aurora kinase A in taxol-resistant breast cancer and its correlation with P-gp. Mol Med Rep. 2011;4(4):739–46. https://doi.org/10.3892/mmr.2011.494.
CAS Article PubMed Google Scholar
Yan M, Wang C, He B, Yang M, Tong M, Long Z, Liu B, Peng F, Xu L, Zhang Y, et al. Aurora-A kinase: a potent oncogene and target for cancer therapy. Med Res Rev. 2016;36(6):1036–79. https://doi.org/10.1002/med.21399.
Yang N, Wang C, Wang Z, Zona S, Lin SX, Wang X, Yan M, Zheng FM, Li SS, Xu B, et al. FOXM1 recruits nuclear aurora kinase A to participate in a positive feedback loop essential for the self-renewal of breast cancer stem cells. Oncogene. 2017;36(24):3428–40. https://doi.org/10.1038/onc.2016.490.
CAS Article PubMed PubMed Central Google Scholar
Birbo B, Madu EE, Madu CO, Jain A, Lu Y. Role of HSP90 in cancer. Int J Mol Sci. 2021;22(19):10317. https://doi.org/10.3390/ijms221910317.
CAS Article PubMed PubMed Central Google Scholar
Kim JY, Cho T-M, Park JM, Park S, Park M, Nam KD, Ko D, Seo J, Kim S, Jung E, et al. A novel HSP90 inhibitor SL-145 suppresses metastatic triple-negative breast cancer without triggering the heat shock response. Oncogene. 2022. https://doi.org/10.1038/s41388-022-02269-y.
Article PubMed PubMed Central Google Scholar
Li D, Marchenko ND, Schulz R, Fischer V, Velasco-Hernandez T, Talos F, Moll UM. Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells. Mol Cancer Res. 2011;9(5):577–88. https://doi.org/10.1158/1541-7786.MCR-10-0534.
CAS Article PubMed PubMed Central Google Scholar
Subramanian C, Grogan PT, Wang T, Bazzill J, Zuo A, White PT, Kalidindi A, Kuszynski D, Wang G, Blagg BSJ, et al. Novel C-terminal heat shock protein 90 inhibitors target breast cancer stem cells and block migration, self-renewal, and epithelial-mesenchymal transition. Mol Oncol. 2020;14(9):2058–68. https://doi.org/10.1002/1878-0261.12686.
CAS Article PubMed PubMed Central Google Scholar
Sumi MP, Ghosh A. Hsp90 in human diseases: molecular mechanisms to therapeutic approaches. Cells. 2022;11(6):976. https://doi.org/10.3390/cells11060976.
CAS Article PubMed PubMed Central Google Scholar
Biebl MM, Buchner J. Structure, function, and regulation of the Hsp90 machinery. Cold Spring Harb Perspect Biol. 2019;11(9):106–17. https://doi.org/10.1101/cshperspect.a034017.
Niu M, Zhang B, Li L, Su Z, Pu W, Zhao C, Wei L, Lian P, Lu R, Wang R, et al. Targeting HSP90 inhibits proliferation and induces apoptosis through AKT1/ERK pathway in lung cancer. Front Pharmacol. 2021;12:724192. https://doi.org/10.3389/fphar.2021.724192.
CAS Article PubMed Google Scholar
Dahiya V, Rutz DA, Moessmer P, Muhlhofer M, Lawatscheck J, Rief M, Buchner J. The switch from client holding to folding in the Hsp70/Hsp90 chaperone machineries is regulated by a direct interplay between co-chaperones. Mol Cell. 2022;82(8):1543-1556.e6. https://doi.org/10.1016/j.molcel.2022.01.016.
CAS Article PubMed Google Scholar
Gopal U, Bohonowych JE, Lema-Tome C, Liu A, Garrett-Mayer E, Wang B, Isaacs JS. A novel extracellular Hsp90 mediated co-receptor function for LRP1 regulates EphA2 dependent glioblastoma cell invasion. PLoS ONE. 2011;6(3):e17649. https://doi.org/10.1371/journal.pone.0017649.
留言 (0)